Peptide News Digest

Australia Orders Peptide Inquiry, Compounded BPC-157 and Semaglutide Recall, Korea's Wegovy Liver Guidance

Australia orders an inquiry into online peptide prescribing, a Texas pharmacy recalls 261 lots of compounded injections, and Korea issues Wegovy liver advice.

10 stories · Covering regulatory, clinical-trials, industry, research

Editor's Note

Peptides sold outside the usual drug channels drew official attention on two continents. Australia's health minister asked a parliamentary committee to examine online peptide prescribing, and in the US a Texas compounding pharmacy recalled 261 lots of injections, most of them peptides such as BPC-157 and TB-500, after an FDA inspection raised sterility questions. A national survey in AJHP shows how the American GLP-1 market splits by channel: among users who knew what they were taking, about three in four who bought through telehealth or a med spa had compounded drugs, against about one in eight who went through a clinic or pharmacy. A University of Queensland survey adds what peptide users report themselves, with men under 25 describing more anxiety, acne, and hair loss than older users. James Brophy's simulation study is worth reading next to the Duke-led head and neck cancer study covered on November 19: by starting follow-up before patients counted as users, he produced hazard ratios as low as 0.39 for a drug that, in his model, did nothing.

Australia's Health Minister Orders a Parliamentary Inquiry Into Online Peptide Prescribing

Health Minister Mark Butler wrote to the House of Representatives health committee on Friday, November 20, asking for an urgent inquiry into the safety and quality of online peptide prescribing, The West Australian reported. Butler said he was "extremely concerned" about TGA reports of unapproved peptides prescribed and delivered through telehealth and one-stop dispensaries. The committee will examine how common approved, off-label, and unapproved peptide use is, how online services that consult, prescribe, and dispense affect patients, whether enforcement powers are strong enough, and what social media platforms owe users. Sport Minister Anika Wells said Sport Integrity Australia has flagged peptides as a risk for athletes. A final report is due by mid-2027.

Texas Compounding Pharmacy Greenwich Rx Recalls 261 Lots of Injections, Including BPC-157, TB-500, Semaglutide, and Tirzepatide

Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, announced a nationwide recall on November 20 of compounded sterile injections dispensed from August 10 to September 21, 2026, citing a possible lack of sterility assurance after an FDA inspection. Its lot list covers 261 lots of 31 products, among them BPC-157 alone and in blends with TB-500, GHK-Cu, and KPV, plus sermorelin, tesamorelin, thymosin alpha-1, NAD+, and semaglutide and tirzepatide mixed with B12, glycine, or L-carnitine. Some were made for another pharmacy, Clove Rx. The company says it has found no contamination and has received no adverse event reports. On October 1 it recalled glutathione injections over possible high endotoxin levels, after two patients needed emergency care following IV use.

Korean Liver Society Issues Wegovy Recommendations for MASH Before Korea Approves the Use

The Korean Association for the Study of the Liver released consensus recommendations on November 20 for semaglutide (Wegovy) in MASH, a use that still awaits approval in Korea, Korea Biomedical Review reported. Candidates are adults with stage F2 to F3 liver fibrosis and no cirrhosis, identified with a FIB-4 blood score followed by an elastography scan, and the society advises against using semaglutide only for liver disease in people with F1 fibrosis or less. Patients would build up from 0.25 mg to 2.4 mg a week and be checked with noninvasive tests after at least 18 months. The advice rests on the Phase 3 ESSENCE trial, in which 36.8% of semaglutide patients and 22.4% on placebo had fibrosis improve without worsening steatohepatitis at 72 weeks.

OLIPOP-Funded Pilot Trial: A Daily Prebiotic Soda Eased Stomach Symptoms More Than Usual Drinks in People on Semaglutide or Tirzepatide

In an open-label pilot run by the contract research firm People Science and funded by OLIPOP, 80 adults taking semaglutide or tirzepatide for weight loss who had at least one digestive symptom were randomized to drink one or two cans a day of OLIPOP prebiotic soda for four weeks or keep their usual fluids. Among the 68 who finished, scores on the Gastrointestinal Symptom Rating Scale fell more with the soda, a between-group difference of 0.53 points, the authors report in Diabetes, Obesity and Metabolism. They call the results preliminary and say larger blinded trials with a matched drink are needed.

TODAY: Texas Woman Paid $3,900 for a Week-Long 'GLP-1 Support Experience' at Hilton Head Health

TODAY reported on November 19 that Teresa Barr, 63, of Rochelle, Texas, paid $3,900 for a week at Hilton Head Health's GLP-1 Support Experience on Hilton Head Island, South Carolina, a program built around strength training, cooking classes with a chef, high-protein meals, and mindful eating. Barr has lost 25 pounds over 18 months on tirzepatide and said she would go back. TODAY says more hotels are offering GLP-1 vacations as more Americans take the drugs. The article does not say whether medical staff take part in the program.

National Survey: 73% of GLP-1 Users Who Bought Through Telehealth or Med Spas Had Compounded Drugs, vs. 13% Through Clinics and Pharmacies

Researchers at North Dakota State University and the University of Texas at El Paso analyzed 976 past-year GLP-1 users in the National Center for Health Statistics' Rapid Surveys System from July and August 2025. Of these users, 18.3% got the drugs through direct-to-consumer telehealth or a medical spa, and 9.2% said they had no clinician prescription. Among users who knew whether their drug was compounded, 73.0% of direct-to-consumer buyers had compounded versions, compared with 12.9% of those who went through a clinician or pharmacy. Direct-to-consumer buyers were also more likely to cut or skip doses because of cost (adjusted odds ratio 4.94) and to report that insurance did not pay, the authors write in AJHP. The survey is cross-sectional and cannot show cause and effect.

University of Queensland-Led Survey of 294 Men Who Inject Peptides: Under-25s Reported More Anxiety, Acne, and Hair Loss

Using the first wave of the International Image and Performance Enhancing Drug Survey, run from October 2025 to March 2026, University of Queensland-led researchers compared 294 cisgender men who had ever injected peptides, split at age 25. Younger men had higher anxiety scores and were more likely to report acne (32.4% vs. 18.7%) and hair loss from the scalp (24.5% vs. 15.0%), but depression, body image concerns, problematic social media use, and most other harms did not differ by age, the team reports in Substance Use & Addiction Journal. The authors say harms are not limited to young men and call for clinician awareness and harm-reduction services. The data are self-reported, and the study did not compare users with non-users.

Simulation Study Argues Large Cancer Benefits Reported for GLP-1 Drugs May Come From Immortal Time Bias

In the Journal of Clinical Epidemiology, James Brophy examined two recent observational studies that counted patients as GLP-1 users only after a second prescription but started their follow-up at the first. Simulating that design 500 times with 5,000 patients each and no true drug effect, he got hazard ratios of 0.39 to 0.72 with longer follow-up and 0.60 to 0.85 with shorter follow-up, close to the published estimates. Starting follow-up when treatment began brought the estimates back to about 1.0. He concludes that the reported cancer associations look more like bias than large causal effects.

Bicycle Therapeutics' Multimeric Bicyclic Peptides Cut SARS-CoV-2 Levels in Animal Studies, Including With Nasal Dosing

Scientists at Bicycle Therapeutics in Cambridge, UK, tested research versions of their multivalent bicyclic peptides in several SARS-CoV-2 animal challenge models: given under the skin or into the nose, before or after exposure, in animals with weakened immune systems, and in transmission experiments. The molecules significantly reduced infectious virus at every study endpoint, the team reports in the Journal of Virology. These are company-run preclinical studies of tool compounds, not tests of a drug candidate in people.

Wayne State Lab Study: Human Peptide LL-37 Sped Up Phage Killing of Drug-Resistant Enterococcus faecium

Researchers led by Wayne State University paired a bacteriophage with daptomycin, ampicillin, or the human host-defense peptide LL-37 against two multidrug-resistant Enterococcus faecium isolates, one of them daptomycin-resistant. In survival assays, regimens that included phage showed greater killing at 4 hours than at 2 hours compared with antibiotics alone, and against the daptomycin-resistant strain LL-37 shortened the lag before the phage suppressed growth, the team reports in JAC-Antimicrobial Resistance. The work was done in lab cultures, and the authors say it supports testing such combinations in the first hours of infection.